Human immunodeficiency virus-1 associated nephropathy (HIVAN): epidemiology, pathogenesis, histology, diagnosis, and medical management.
Human immunodeficiency virus-associated nephropathy (HIVAN) is a very distinct, unique, clinico-pathological syndrome, and a structural type of renal failure that is the most common cause of chronic renal failure in patients who are HIV-seropositive. Early referral and a long-term, primary care approach can improve patient outcomes. Careful adjustments of prescription doses with regularly scheduled, and at times frequent, laboratory testing will yield, optimal health, improve the quality of life, and most importantly, will decrease the incidence of morbidity and mortality in those individuals afflicted with both HIV and HIVAN.
Lochner
Michelle L
ML
Inpatient Dialysis Unit/Division of Nephrology and Hypertension, Mayo Clinic/Mayo Medical Center, Rochester, MN, USA.
Wolf
Andrea
A
D016263:AIDS-Associated Nephropathy / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000379:methods; D018791:CD4 Lymphocyte Count; D015984:Causality; D002423:Cause of Death; D018450:Disease Progression; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D042241:Early Diagnosis; D015497:HIV-1; D006801:Humans; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000821:virology; D009017:Morbidity; D011159:Population Surveillance; D011320:Primary Health Care; D012017:Referral and Consultation; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D019562:Viral Load
D000806:Angiotensin-Converting Enzyme Inhibitors; D000893:Anti-Inflammatory Agents